Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Allez

Showing results (151-160 of 205) with videos related to

Pageof 21
Sort By:
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Cell Host & Microbe|July 16, 2024
Mitochondrial perturbation in the intestine causes microbiota-dependent injury and gene signatures discriminative of inflammatory diseaseElisabeth Urbauer, Doriane Aguanno, Nora Mindermann, et al.
Gastroenterology|February 26, 2026
Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn's diseaseLéonard Dubois, Alexandre Chaussard, Philippe Seksik, et al.
Clinical and Translational Gastroenterology|July 31, 2023
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube DigestifLucas Guillo, Guillaume Savoye, Aurélien Amiot, et al.
Gut|November 25, 2024
Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trialAurelien Amiot, Philippe Seksik, Antoine Meyer, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort studyPauline Wils, Philippe Seksik, Carmen Stefanescu, et al.
The American Journal of Gastroenterology|December 14, 2016
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND GroupMathurin Fumery, Philippe Seksik, Claire Auzolle, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 16, 2009
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infectionShomron Ben-Horin, Maya Margalit, Peter Bossuyt, et al.
Pageof 21

Showing results (151-160 of 205) with videos related to

Sort By:
Pageof 21
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Cell Host & Microbe|July 16, 2024
Mitochondrial perturbation in the intestine causes microbiota-dependent injury and gene signatures discriminative of inflammatory diseaseElisabeth Urbauer, Doriane Aguanno, Nora Mindermann, et al.
Gastroenterology|February 26, 2026
Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn's diseaseLéonard Dubois, Alexandre Chaussard, Philippe Seksik, et al.
Clinical and Translational Gastroenterology|July 31, 2023
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube DigestifLucas Guillo, Guillaume Savoye, Aurélien Amiot, et al.
Gut|November 25, 2024
Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trialAurelien Amiot, Philippe Seksik, Antoine Meyer, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort studyPauline Wils, Philippe Seksik, Carmen Stefanescu, et al.
The American Journal of Gastroenterology|December 14, 2016
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND GroupMathurin Fumery, Philippe Seksik, Claire Auzolle, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 16, 2009
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infectionShomron Ben-Horin, Maya Margalit, Peter Bossuyt, et al.
Pageof 21